
Recurrent vulvovaginal candidiasis affects five percent of women of child-bearing age. The most common organism is Candidia albicans, but an increasing number of infections are caused by nonalbicans species. Fungal culture directs treatment as nonalbicans species may be azole resistant. C. albicans will respond to anyazole antifungal. Treat C. glabrata with boric acid. Maintenance therapy should be started immediately after treatment of the acute episode and should last for six months.
Antifungal Agents, Episode of Care, Candida glabrata, Ketoconazole, Boric Acids, Acute Disease, Candida albicans, Secondary Prevention, Humans, Female, Candidiasis, Vulvovaginal
Antifungal Agents, Episode of Care, Candida glabrata, Ketoconazole, Boric Acids, Acute Disease, Candida albicans, Secondary Prevention, Humans, Female, Candidiasis, Vulvovaginal
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 14 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
